Tandem high-dose therapy (HDT) for multiple myeloma: Recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion

British Journal of Haematology

Volumn 123, Issue 1, 2003, Pages 103-105

  Baron, Frédéric ^a   Frère, Pascale ^a   Fillet, Georges ^a   Beguin, Yves ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Autologous stem cell transplantation; Erythropoietin; Myeloma; Recombinant erythropoietin; Tandem transplantation

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; BLOOD TRANSFUSION; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REOPERATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0141484378     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04556.x     Document Type: Article

References (12)

1. Andre, M., Baudoux, E., Bron, D., Canon, J.L., D'Hondt, V., Fassotte, M.F., D'Hondt, L., Fillet, G., Humblet, Y., Jerusalem, G., Vermeulen, P., Symann, M. & Beguin, Y. (2003) Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion, 43, 50-57.
2. Attal, M., Harousseau, J.L., Facon, T., Guilhot, F. & Doyen, C. (2002) Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the intergroupe francophone du myelome. Blood, 100, 7a.
3. Baron, F. & Beguin, Y. (2003) Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation (alloPBSCT) when started soon after engraftment. Haematologica, 88, 718-720.
4. Baron, F., Sautois, B., Baudoux, E., Matus, G., Fillet, G. & Beguin, Y. (2002a) Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 30, 546-554.
5. Baron, F., Fillet, G. & Beguin, Y. (2002b) Erythropoiesis after non-myeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. Transplantation, 74, 1692-1696.
6. Beguin, Y. (2002) Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica, 87, 1209-1221.
7. Beguin, Y., Clemons, G.K., Pootrakul, P. & Fillet, G. (1993) Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood, 81, 1067-1076.
8. Beguin, Y., Baron, F. & Fillet, G. (1998) Influence of marrow activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica, 83, 1076-1081.
9. Goodnough, L.T., Brecher, M.E., Kanter, M.H. & AuBuchon, J.P. (1999) Transfusion medicine. First of two parts - blood transfusion. New England Journal of Medicine, 340, 438-447.
10. Link, H., Boogaerts, M.A., Fauser, A.A., Slavin, S., Reiffers, J., Gorin, N.C., Carella, A.M., Mandelli, F., Burdach, S. & Ferrant, A. (1994) A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood, 84, 3327-3335.
11. Ponchio, L., Zambelli, A., De Stefano, A., Robustelli Della Cuna, F.S., Perotti, C. & Pedrazzoli, P. (2000) Transfusion requirement can be abolished by epoietin-a and autologous platelet predeposit in patients receiving high dose chemotherapy with stem cell support. Haematologica, 85, 219-220.
12. R'Zik, S. & Beguin, Y. (2001) Serum soluble transferrin receptor concentration is an accurate estimate of the mass of tissue receptors. Experimental Hematology, 29, 677-685.